Epidemiology of HBV S-gene mutants in the Liguria Region, Italy Implications for surveillance and detection of new escape variants

Human Vaccines and Immunotherapeutics

Volumn 9, Issue 3, 2013, Pages 568-571

  Sticchi, Laura ^a,b   Caligiuri, Patrizia ^a   Cacciani, Roberto ^a   Alicino, Cristiano ^a   Bruzzone, Bianca ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Escape mutants; G145R; HBsAg; HBV genotyping; HBV mutants

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; VIRUS DNA; HEPATITIS B ANTIBODY; MUTANT PROTEIN;

ADOLESCENT; ADULT; AGED; ANALYTICAL EQUIPMENT; ANIMAL CELL; CHILD; CONFERENCE PAPER; DNA EXTRACTION; FEMALE; GENE SEQUENCE; GENETIC EPIDEMIOLOGY; GENOTYPE; HBV S GENE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PATIENT MONITORING; PREVALENCE; SCHOOL CHILD; SEROLOGY; VIRUS GENE; VIRUS LOAD; VIRUS MUTANT; VIRUS MUTATION; AMINO ACID SUBSTITUTION; BLOOD; CHEMISTRY; COHORT ANALYSIS; DNA SEQUENCE; EPIDEMIOLOGICAL MONITORING; EPIDEMIOLOGY; GENETICS; IMMUNOASSAY; IMMUNOLOGY; ISOLATION AND PURIFICATION; LABORATORY DIAGNOSIS; MASS SCREENING; MIDDLE AGED; PROCEDURES; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINO ACID SUBSTITUTION; CHILD; COHORT STUDIES; DNA, VIRAL; EPIDEMIOLOGICAL MONITORING; FALSE NEGATIVE REACTIONS; FEMALE; GENOTYPE; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; IMMUNOASSAY; ITALY; MALE; MASS SCREENING; MIDDLE AGED; MUTANT PROTEINS; PREVALENCE; SEQUENCE ANALYSIS, DNA; YOUNG ADULT;

EID: 84874699853     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.23236     Document Type: Conference Paper

References (17)

1. World Healthorganization. Hepatitis B; July 2012; Available from: http://www.who.int/mediacentre/factsheets/fs204/en/
2. Colvin HM, Mitchell AE. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: National Academies Press; 2010.
3. World Healthorganization.vaccines and biological: WHOvaccine preventable disease monitoring system. Global summary 2009. Available at: www.who. int/immunization/documents/WHO-IVB-2009/en/index.html. Assessed October 23, 2012.
4. Basuni AA, Butterworth L, Cooksley G, Locarnini S, Carman WF. Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries.vaccine 2004; 22:2791-9; PMID:15246613; http://dx.doi.org/10. 1016/j.vaccine.2004.01.046. (Pubitemid 38900656)
5. Fitzsimons D, François G, Hall A, McMahon B, Meheus A, Zanetti A, et al. Long-term efficacy of hepatitis Bvaccine, booster policy, and impact of hepatitis B virus mutants.vaccine 2005; 23:4158-66; PMID:15964484; http://dx.doi.org/10.1016/j.vaccine. 2005.03.017. (Pubitemid 40814591)
6. Zanetti AR, Tanzi E, Manzillo G, Maio G, Sbreglia C, Caporaso N, et al. Hepatitis B variant in Europe. Lancet 1988; 2:1132-3; PMID:2460710; http://dx.doi.org/10.1016/S0140-6736(88)90541-7.
7. Sheldon J, Soriano V. Hepatitis B virus escape mutants induced by antiviral therapy. J Antimicrob Chemother 2008; 61:766-8; PMID:18218641; http://dx.doi.org/10.1093/jac/dkn014.
8. Carman WF, Zanetti AR, Karayiannis P, Waters J, Manzillo G, Tanzi E, et al.vaccine-induced escape mutant of hepatitis B virus. Lancet 1990; 336:325-9; PMID:1697396; http://dx.doi.org/10.1016/0140-6736(90)91874-A.
9. Hawkins AE, Gilson RJ, Gilbert N, Wreghitt TG, Gray JJ, Ahlers-de Boer I, et al. Hepatitis B virus surface mutations associated with infection after liver transplantation. J Hepatol 1996; 24:8-14; PMID:8834018; http://dx.doi.org/10.1016/S0168-8278(96)80179-6.
10. Zuckerman JN, Zuckerman AJ. Mutations of the surface protein of hepatitis B virus. Antiviral Res 2003; 60:75-8; PMID:14638401; http://dx.doi.org/10.1016/ j.antiviral.2003.08.013. (Pubitemid 37452449)
11. Melegari M, Bruno S, Wands Jr. Properties of hepatitis B virus pre-S1 deletion mutants.virology 1994; 199:292-300; PMID:8122362; http://dx.doi.org/10. 1006/viro.1994.1127.
12. Fernholz D, Galle PR, Stemler M, Brunetto M, Bonino F, Will H. Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier.virology 1993; 194:137-48; PMID:8480417; http://dx.doi.org/10.1006/viro. 1993.1243.
13. Mele A, Tancredi F, Romanò L, Giuseppone A, Colucci M, Sangiuolo A, et al. Effectiveness of hepatitis B vaccination in babies born to hepatitis B surface antigenpositive mothers in Italy. J Infect Dis 2001; 184:905-8; PMID:11509998; http://dx.doi.org/10.1086/323396.
14. Clements CJ, Coghlan B, Creati M, Locarnini S, Tedder RS, Torresi J. Global control of hepatitis B virus: does treatment-induced antigenic change affect immunization? Bull World Healthorgan 2010; 88:66-73; PMID:20428355; http://dx.doi.org/10.2471/BLT.08.065722.
15. Gerlich WH, Bremer C, Saniewski M, Schüttler CG, Wend UC, Willems WR, et al. Occult hepatitis B virus infection: detection and significance. Dig Dis 2010; 28:116-25; PMID:20460899; http://dx.doi.org/10.1159/000282074.
16. Bremer CM, Saniewski M, Wend UC, Torres P, Lelie N, Gerlich WH, et al. Transient occult hepatitis B virus infection in a blood donor with high viremia. Transfusion 2009; 49:1621-9; PMID:19413737; http://dx.doi.org/10.1111/j.1537- 2995.2009.02188.x.
17. Coleman PF. Detecting hepatitis B surface antigen mutants. Emerg Infect Dis 2006; 12:198-203; PMID:16494742; http://dx.doi.org/10.3201/eid1203.050038.